Health Canada Press Releases
December 01, 2020
The Marketed Health Products Directorate regarding the summary safety review for Bacitracin for Injection Products and the potential risks of Nephrotoxicity and Anaphylactic Reactions is available here. The summary safety review is available here.
For the Marketed Health Products Directorate regarding the summary safety review for Direct-acting antiviral products containing a Protease Inhibitor and the Potential Risks of Hepatic Decompensation and Hepatic Failure click here. For the summary safety review, click here.
October 29, 2020
Re: Health Canada has published a summary safety review regarding Brilinta (ticagrelor).
The Summary Safety Review is available here